Study #2021-0342
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects with Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
MD Anderson Study Status
Not Accepting
Treatment Agent
Sacituzumab Govitecan-hziy
Description
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic Solid Tumor, Liver Failure
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-927-2548
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.